Brian McKelligon's Insider Trades & SAST Disclosures
Brian McKelligon's most recent trade in Akoya Biosciences Inc was a trade of 7,550 Common Stock done at an average price of $1.7 . Disclosure was reported to the exchange on March 23, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Brian McKelligon.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.70 per share. | 23 Mar 2025 | 7,550 | 420,126 | - | 1.7 | 12,835 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.63 per share. | 01 Mar 2025 | 8,257 | 427,676 | - | 1.6 | 13,459 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.63 per share. | 01 Mar 2025 | 7,550 | 435,933 | - | 1.6 | 12,307 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 19 Nov 2024 | 218,750 | 443,483 | - | 0 | Common Stock | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 11 Jun 2024 | 7,500 | 232,233 | - | 0.3 | 2,273 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2024 | 7,500 | 275,629 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.08 per share. | 11 Jun 2024 | 7,500 | 224,733 | - | 2.1 | 15,630 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2024 | 7,500 | 283,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 2.01 per share. | 06 Jun 2024 | 7,500 | 224,733 | - | 2.0 | 15,064 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 06 Jun 2024 | 7,500 | 232,233 | - | 0.3 | 2,273 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.79 per share. | 23 Mar 2024 | 7,135 | 224,733 | - | 4.8 | 34,177 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 20 Mar 2024 | 7,500 | 239,368 | - | 0.3 | 2,273 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.97 per share. | 20 Mar 2024 | 7,500 | 231,868 | - | 5.0 | 37,243 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Mar 2024 | 7,500 | 290,629 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.94 per share. | 13 Mar 2024 | 7,500 | 224,368 | - | 4.9 | 37,035 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 13 Mar 2024 | 7,500 | 239,368 | - | 0.3 | 2,273 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Mar 2024 | 7,500 | 298,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.94 per share. | 13 Mar 2024 | 7,500 | 231,868 | - | 4.9 | 37,043 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 175,000 | 175,000 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 Feb 2024 | 87,500 | 240,063 | - | 0 | Common Stock | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.03 per share. | 22 Feb 2024 | 8,195 | 231,868 | - | 6.0 | 49,416 | Common Stock |
| Akoya Biosciences Inc | McKelligon Brian | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.48 per share. | 19 Dec 2023 | 7,500 | 152,563 | - | 4.5 | 33,566 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 19 Dec 2023 | 7,500 | 160,063 | - | 0.3 | 2,273 | Common Stock |
| Akoya Biosciences Inc | McKelligon Brian | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 19 Dec 2023 | 7,500 | 305,629 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 12 Dec 2023 | 7,500 | 160,063 | - | 0.3 | 2,273 | Common Stock |
| Akoya Biosciences Inc | McKelligon Brian | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Dec 2023 | 7,500 | 313,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President and CEO | Sale of securities on an exchange or to another person at price $ 4.25 per share. | 12 Dec 2023 | 7,500 | 152,563 | - | 4.2 | 31,871 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Sale of securities on an exchange or to another person at price $ 5.71 per share. | 06 Jun 2023 | 5,000 | 152,563 | - | 5.7 | 28,537 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jun 2023 | 5,000 | 328,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 06 Jun 2023 | 5,000 | 157,563 | - | 0.3 | 1,515 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.69 per share. | 23 Mar 2023 | 7,437 | 152,563 | - | 7.7 | 57,191 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Mar 2023 | 5,000 | 333,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 14 Mar 2023 | 5,000 | 165,000 | - | 0.3 | 1,515 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Sale of securities on an exchange or to another person at price $ 9.13 per share. | 14 Mar 2023 | 4,774 | 160,226 | - | 9.1 | 43,610 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | Director, President/CEO | Sale of securities on an exchange or to another person at price $ 9.92 per share. | 14 Mar 2023 | 226 | 160,000 | - | 9.9 | 2,241 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 160,000 | 160,000 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 Feb 2023 | 80,000 | 160,000 | - | 0 | Common Stock | |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 06 Dec 2022 | 5,000 | 85,000 | - | 0.3 | 1,515 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Dec 2022 | 5,000 | 338,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Sale of securities on an exchange or to another person at price $ 12.08 per share. | 06 Dec 2022 | 5,000 | 80,000 | - | 12.1 | 60,415 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 07 Sep 2022 | 5,000 | 85,000 | - | 0.3 | 1,515 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Sale of securities on an exchange or to another person at price $ 12.83 per share. | 07 Sep 2022 | 5,000 | 80,000 | - | 12.8 | 64,170 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 Sep 2022 | 5,000 | 343,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Sale of securities on an exchange or to another person at price $ 10.25 per share. | 15 Jun 2022 | 5,000 | 80,000 | - | 10.3 | 51,260 | Common Stock |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Jun 2022 | 5,000 | 348,129 | - | - | Employee Stock Option (Right to Buy) | |
| Akoya Biosciences Inc | Brian McKelligon | President/CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.30 per share. | 15 Jun 2022 | 5,000 | 85,000 | - | 0.3 | 1,515 | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges